Serpin E1, also known as Plasminogen Activator Inhibitor-1 (PAI-1), is the primary inhibitor of urokinase-type and tissue-type plasminogen activators (uPA and tPA) which convert Plasminogen to Plasmin. The PA-Plasmin system is involved in fibrinolysis, tissue fibrosis, angiogenesis, wound healing, tumor cell invasion and metastasis, and obesity. Serpin E1 can promote clot formation, arterial re-endothelialization, and neointima formation while protecting against vascular intima thickening. It binds Vitronectin and inhibits vascular smooth muscle cell and endothelial cell adhesion, proliferation, and motility. Serpin E1 binds and induces the LRP-dependent internalization of cell surface complexes containing uPA, uPAR, and Integrin alpha V beta 3. Serpin E1 secretion is upregulated during inflammation, physical injury, and exposure to Angiotensin II.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.